FGFR2 and endometrial cancer: Consistently, in endometrial cancer, research utilizing patient-derived xenograft (PDX) and organoid (PDXO) models has demonstrated that tumors with high FGFR2-IIIc expression exhibit heightened sensitivity to FGFR inhibitors such as BGJ398 and pemigatinib.